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Lymphocytosis After Treatment With Dasatinib in Chronic
Myeloid Leukemia: Effects on Response and Toxicity
Charles A. Schiffer, MD1; Jorge E. Cortes, MD2; Andreas Hochhaus, MD3; Giuseppe Saglio, MD4; Philipp le Coutre, MD5;
Kimmo Porkka, MD, PhD6; Satu Mustjoki, MD, PhD6; Hesham Mohamed, MD7; and Neil P. Shah, MD, PhD8
BACKGROUND: The proliferation of clonal cytotoxic T-cells or natural killer cells has been observed after dasatinib treatment in small
studies of patients with chronic myeloid leukemia (CML). METHODS: The incidence of lymphocytosis and its association with
response, survival, and side effects were assessed in patients from 3 large clinical trials. Overall, 1402 dasatinib-treated patients with
newly diagnosed CML in chronic phase (CML-CP), CML-CP refractory/intolerant to imatinib, or with CML in accelerated or myeloid-
blast phase were analyzed. RESULTS: Lymphocytosis developed in 32% to 35% of patients and persisted for >12 months. This was not
observed in the patients who received treatment with imatinib. Dasatinib-treated patients in all stages of CML who developed lym-
phocytosis were more likely to achieve a complete cytogenetic response, and patients who had CML-CP with lymphocytosis were
more likely to achieve major and deep molecular responses. Progression-free and overall survival rates were significantly longer in
patients with CML-CP who were refractory to or intolerant of imatinib and had lymphocytosis. Pleural effusions developed more com-
monly in patients with lymphocytosis. CONCLUSIONS: Overall, lymphocytosis occurred and persisted in many dasatinib-treated
patients in all phases of CML. Its presence was associated with higher response rates, significantly longer response durations, and
increased overall survival, suggesting an immunomodulatory effect. Prospective studies are warranted to characterize the functional
activity of these cells and to assess whether an immunologic effect against CML is detectable. Cancer 2016;122:1398-407. VC 2016 The
Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the
terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited and is not used for commercial purposes.
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INTRODUCTION
Dasatinib is a multitargeted tyrosine kinase inhibitor (TKI) approved for the treatment of adults with newly diagnosed,
Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML) in chronic phase (CML-CP); adults with
CML-CP, CML in accelerated phase (CML-AP), CML in myeloid-blast phase (CML-MBP), or CML in lymphoid-blast
phase (CML-LBP) who have resistance/intolerance to prior therapy, including imatinib; and adults with Ph-positive,
acute lymphoblastic leukemia (ALL) who have resistance/intolerance to prior therapy.1 Although dasatinib primarily
inhibits the constitutively active tyrosine kinase breakpoint cluster region/Abelson 1 proto-oncogene (BCR-ABL1),2 it
was initially developed as an SRC family kinase inhibitor.3 It also acts on other kinases, including KIT, platelet-derived
growth factor receptor, the ephrin-A receptor, and TEC family kinases.2-6
The immunosuppressive effects of dasatinib were initially observed in preclinical studies.3 The known effects of
dasatinib on normal hematopoiesis and lymphopoiesis are limited, but in vitro and animal models suggest that dasatinib
may inhibit lymphocyte proliferation and function without inducing apoptosis.7-11 ABL1 and SRC family kinase signal-
ing pathways, both of which are inhibited by dasatinib, are essential for T-cell proliferation, function, and survival.12-14
Therefore, it was somewhat surprising that clonal expansion of cytotoxic T-cells or natural killer (NK) cells (T/NK)
was detected (median time to detection, 1-4 months) after initiation of dasatinib therapy in small studies of CML or
patients with Ph-positive ALL.15-25 Few studies have evaluated whether this population was present before treatment,
although Kreutzman et al25 demonstrated expansion of a BCR-ABL1–negative lymphocyte population with T-cell
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receptor c/d rearrangements (present at the time of CML
diagnosis) after dasatinib treatment. Some analyses have
suggested that T/NK lymphoproliferation was associated
with higher than expected rates of cytogenetic and molec-
ular response, particularly in patients with advanced dis-
ease, suggesting an immunomodulatory effect.16-21 Also,
an increase in certain side effects, such as pleural effusions,
has been reported.20-24 Resolution of pleural effusion and
T/NK lymphocytosis has been described after switching
from dasatinib to another TKI.26 T/NK cell expansion
has not been described after CML treatment with other
TKIs. To our knowledge, no prior study has systemati-
cally evaluated the effects of these findings on response to
treatment, progression-free survival (PFS), or overall sur-
vival (OS).
For an illustrative example, a woman who pro-
gressed to CML-MBP despite prior imatinib treatment
was treated with dasatinib alone in June 2005 and, as of
her last visit in late 2015, remains in remission with unde-
tectable BCR-ABL1 transcripts (Fig. 1). Her treatment
was complicated by the development of a chronic pleural
effusion. Lymphocytosis, reaching> 7000/mm3, had
been present for approximately 9 years, with cells charac-
terized as T/NK cells by flow cytometry. Although ele-
vated on most occasions, several lymphocyte counts were
in the normal range, which may reflect the documented
pharmacodynamic effect of the plasma level of dasatinib
and the lymphocyte count.27
To expand on these observational studies, we ana-
lyzed the incidence of lymphocytosis in a large group of
patients (n5 1402) with CML-CP, CML-AP, and
CML-MBP who received treatment with dasatinib and
were enrolled in prospective clinical trials with long-term
follow-up. Here, we report our results describing the asso-
ciation between the development of lymphocytosis and
initial response, long-term outcome, and the development
of pleural effusions.
MATERIALS AND METHODS
Study Design and Patient Eligibility
We previously presented data in abstract form from
patients with CML-CP in the “Src/ABL Tyrosine Kinase
Inhibition Activity Research Trials of Dasatinib”
(START) Program’s phase 2, second-line START-A,
START-B, START-C, and START-R trials and the phase
3 Dasatinib Versus Imatinib Study in Treatment-Naive
CML Patients (DASISION) trial (CA180-056; clinical-
trials.gov NCT00481247).20,28 This report focuses on
randomized trials because of their closely monitored,
long-term follow-up. Retrospective analyses were con-
ducted using 5-year, long-term data from dasatinib-treated
patients with newly diagnosed CML-CP in the DASI-
SION trial29; 7-year, long-term data from patients with
CML-CP resistant/intolerant to imatinib in the phase 3
dose-optimization trial (CA180-034; NCT00123474)30;
and 5-year, long-term data from patients with CML-AP or
CML-MBP who were resistant to/intolerant of imatinib in
the phase 3 dose-optimization trial for patients with
advanced-phase CML (CA180-035; NCT00123487).31
Entry criteria for these studies have been published
elsewhere.29-31 Briefly, eligible patients in the DASISION
trial included adults with cytogenetically confirmed, Ph-
positive CML-CP within 3 months from diagnosis who
had adequate hepatic and renal function and no serious
medical conditions. No prior CML therapy was permitted
except for anagrelide or hydroxyurea. Patients received
treatment with either dasatinib 100mg once daily or
imatinib 400mg once daily. Patients in CA180-034 were
required to be aged 18 years and to have Ph-positive
CML-CP with primary or acquired resistance/intolerance
to imatinib. Patients in CA180-034 received dasatinib at
doses of 100mg once daily, 140mg once daily, 50mg
twice daily, or 70mg twice daily. In CA180-035, patients
with CML-AP, CML-MBP/LBP, or Ph-positive ALL
aged 18 years and who had developed primary or
acquired resistance/intolerance to imatinib were enrolled.
Patients in CA180-035 received treatment with dasatinib
either 140mg once daily or 70mg twice daily. Each of the
3 trials was conducted in accordance with the Declaration
of Helsinki and was approved by local ethics committees
or institutional review boards. All patients gave written
informed consent.
Lymphocytosis
Lymphocytosis was defined as lymphocyte counts
>3.63 109/L on at least 2 consecutive occasions after 28
days of treatment. Complete blood counts, typically with
automated differential counts, were performed at least
weekly for the initial 1 to 2 months of treatment, then
monthly, and every 3 months thereafter during long-term
follow-up. In general, total white blood cell counts were
normal in dasatinib-treated patients after 1 to 2 months
(within accuracy range for differential counts). The tim-
ing of dasatinib dosing relative to lymphocyte assessments
was not known. Flow cytometry was not performed,
because the observation of lymphocytosis was not consid-
ered until after these trials were under way. We did not
study patients in lymphoid blastic phase because serial
slides were unavailable. The sole use of an automated
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lymphocyte count may have caused potential confusion
between lymphoblasts and other lymphoid elements.
Analyses
The incidence, timing, and duration of lymphocytosis
were determined. The duration of lymphocytosis was
defined as the interval between the date of original detec-
tion and the date of last available follow-up sample that
was positive for lymphocytosis. Rates of complete cytoge-
netic response (CCyR) (based on analysis of 20 meta-
phases), major molecular response (MMR) (BCR-ABL1
transcripts 0.1% on the International Scale [IS]),
molecular response4.5 (MR4.5) (BCR-ABL1 transcripts
 0.0032% on the IS), PFS, OS, and incidence of pleural
effusion were compared between patients with and with-
out lymphocytosis. Landmark analyses of PFS and OS for
patients with or without lymphocytosis at 3 months were
also performed. Progression in patients with CML-CP
was defined as an increasing white blood cell count; loss of
a complete hematologic response or a major cytogenetic
response; an increase 30% in Ph-positive metaphases;
or transformation to CML-AP, CML-MBP, or CML-
LBP.
The log-rank test was used to calculate P values for
PFS and OS (Fig. 2), the Fisher exact test was used to cal-
culate P values for incidences of responses and pleural
effusion, and logistic regression was used to examine the
relation between the binary response variable lymphocy-
tosis (yes/no) and a set of predictive variables. Statistical
comparisons were not prespecified, and comparisons were
not adjusted for multiplicity; therefore, P values are pro-
vided solely for informative purposes.
RESULTS
Patients and Incidence of Lymphocytosis
Patients’ disease and demographic characteristics at base-
line in the different studies are provided in Table 1. The
median age ranged from 46 to 56 years, and there were
slightly more men than women. For patients in the
second-line dasatinib studies, the median duration of
prior imatinib therapy was from 16 to 40 months, and up
to 46% of patients received 800mg daily. Overall, 74%
to 81% of patients were resistant to imatinib, whereas
16% to 26% of patients were intolerant. The baseline me-
dian lymphocyte counts in treated patients ranged from
1.73 109/L to 3.03 109/L in the 3 studies. A minority of
patients (range, 14%-41%) had a single lymphocyte
count >3.63 109/L at enrollment. However, most such
patients in chronic and blast phases had elevated white
blood cells at study entry, and automated differential
counts likely are less accurate in such circumstances. In
contrast, our definition of lymphocytosis demanded that
the count be elevated on at least 2 consecutive occasions,
and this almost always occurred at a time when the total
white blood cell count was relatively normal after the
cytoreductive effects from the dasatinib.
The cumulative incidence of lymphocytosis was
comparable across all phases of CML (range, 32%-35%)
(Table 2) and was similar in patients who had CML-CP,
irrespective of prior imatinib treatment. The maximal
lymphocyte counts and the counts at the time of initial
detection of lymphocytosis are provided in Table 2. There
was no difference in the occurrence of lymphocytosis
among the different dasatinib doses and schedules eval-
uated in study CA180-034. The distribution of Hasford
risk scores was similar for patients who did and did not de-
velop lymphocytosis in the DASISION trial (data not
shown), and there was no effect of age or sex. Lymphocy-
tosis developed rapidly after dasatinib initiation, with a
median time to detection of 3 to 5 months. A first inci-
dence of lymphocytosis after 5 to 6 months of treatment
was very uncommon; however, many patients, particu-
larly those with CML-AP and CML-MBP, were no longer
receiving dasatinib at that time (median on-treatment fol-
low-up, 6.1 months). In the DASISION study, lympho-
cytosis was observed in 35% and 8% of dasatinib- and
imatinib-treated patients, respectively, and was almost
invariably transient in the imatinib-treated patients (data
not shown).
The duration of lymphocytosis varied across the
different phases of CML (range, 1.4-33.8 months)
(Table 2), possibly influenced by the differing rates of
dasatinib discontinuation, specifically in patients with
advanced disease. In addition, lymphocytosis may have
been missed in some patients because only single samples
were obtained approximately every 3 months during
long-term follow-up. Thus, the median durations of lym-
phocytosis of 33.8 and 12.9 months in patients with
CML-CP in the DASISION and CA180-034 trials,
respectively, may have been underestimated. Nonetheless,
at minimum, from 52% to 77% of patients with CML-
CP who developed lymphocytosis had it persist for
12 months. Furthermore, it is likely that some patients
in whom lymphocytosis was no longer detected had dis-
continued dasatinib treatment.
Response to Treatment
Response to treatment was assessed at approximately 3-
month intervals. Lymphocytosis was associated with stat-
istically significantly higher rates of CCyR in all phases of
Original Article
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CML (newly diagnosed CML-CP, P5 .0166; resistant/
intolerant CML-CP, P5 .0011; CML-AP, P5 .0004;
CML-MBP, P5 .0030) (Table 3). Furthermore, the rates
of MMR and MR4.5 were statistically significantly
increased in patients who had CML-CP with lymphocy-
tosis in both the DASISION trial (MMR, P5 .0438;
MR4.5, P5 .0253), which evaluated newly diagnosed
patients, and in the CA180-034 trial, which evaluated
imatinib-resistant/intolerant patients (MMR, P5 .0010;
MR4.5, P5 .0068).
PFS (P5 .0119) and OS (P5 .0349) were signifi-
cantly longer in patients with lymphocytosis from the
TABLE 1. Baseline Demographic and Disease Characteristics of Randomized Patients
DASISIONa CA180-034b CA180-035b
Characteristic CML-CP, n5 259 CML-CP, n5670 CML-AP, n5 320 CML-MBP, n5 153
Median age, y 46 55 56 50
Sex, %
Men 56 47 57 54
Women 44 53 43 46
Prior treatment, %
Stem cell transplantation NA 4 6 12
Interferon-a NA 52 54 38
Chemotherapy NA 26 45 57
Prior imatinib therapy
Median duration, mo NA 27 40 16
Highest dose 800mg/d, % NA 33 43 46
Best response to prior imatinib, %
CHR NA 84 76 64
MCyR NA 41 29 32
Imatinib-resistant, % NA 74 77 81
Imatinib-intolerant, % NA 26 23 16
Abbreviations: CA180-034, 7-year, long-term data from patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP) who were resistant to/intoler-
ant of imatinib in the phase 3 dose-optimization trial; CA180-035, 5-year, long-term data from patients with CML in accelerated phase (CML-AP) or in myeloid-
blast phase (CML-MBP) who were resistant to/intolerant of imatinib in the phase 3 dose-optimization trial for advanced-phase CML; CHR, complete hemato-
logic response; DASISION, Dasatinib Versus Imatinib Study in Treatment-Naive CML Patients; MCyR, major cytogenetic response; NA, not applicable.
a Data shown are for the dasatinib treatment arm only.
b Data include all dasatinib doses.
TABLE 2. Incidence, Timing, and Duration of Lymphocytosis During Treatment With Dasatinib
DASISIONa CA180-034b CA180-035b
Variable CML-CP, n5 258 CML-CP, n5 662 CML-AP, n5 316 CML-MBP, n5148
Incidence, % 35 32 35 34
Time to onset: Median (range), mo 5.2 (1.0-35.9) 3.2 (1.0-72.0) 3.5 (1.0-25.1) 2.6 (1.0-16.3)
On-treatment follow-up: Median (range), mo 60.5 (0-72.7) 29.8 (0.1-92.9) 6.1 (0-67.0)
Lymphocyte counts in those with
lymphocytosis at the time of initial
detection and maximal lymphocyte
count: Median (range),3 103/lL
At initial detection 4.2 (3.6-8.7) 4.2 (2.8-1350.0)e 4.5 (3.6-32.9)e 5.1 (3.6-25.3)e
Maximal 5.4 (3.7-29.1)e 5.7 (3.7-5226.0)e 6.9 (3.9-215.6)e 9.5 (3.9-66.2)e
Duration of lymphocytosis: Median (range), moc 33.8 (28.3-37.21)d 12.9 (11.7-15.11)d 8.4 (4.9-12.21)d 1.4 (0.6-2.91)d
Lymphocytosis duration> 12 mo, %d 77 52 42 18
Abbreviations: CA180-034, 7-year, long-term data from patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP) who were resistant to/intoler-
ant of imatinib in the phase 3 dose-optimization trial; CA180-035, 5-year, long-term data from patients with CML in accelerated phase (CML-AP) or in myeloid-
blast phase (CML-MBP) who were resistant to/intolerant of imatinib in the phase 3 dose-optimization trial for advanced-phase CML; DASISION, Dasatinib Ver-
sus Imatinib Study in Treatment-Naive CML Patients.
a Data are shown for the dasatinib treatment arm only.
b Data include all dasatinib doses.
c Values shown are only for the patients who had lymphocytosis.
d Some patients had ongoing lymphocytosis at the time of analysis, as indicated by a plus sign.
e The upper levels of these ranges should be interpreted with caution, because they could represent cells other than lymphocytes, particularly in the patients
with CML-AP and CML-MBP.
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CA180-034 trial (Fig. 2c,d), which had the longest
follow-up of any of the studies analyzed (7 years). The
separation of the curves began at approximately 2 years af-
ter the start of treatment. Although patients with newly
diagnosed CML-CP who had lymphocytosis had more
prolonged PFS and OS than patients without lymphocy-
tosis, these results were not significantly different with 5
years of follow-up (PFS, P5 .1133; OS, P5 .3452) (Fig.
2a,b). There were no significant differences in PFS
(CML-AP, P5 .23; CML-MBP, P5 .0615) or OS
(CML-AP, P5 .7844; CML-MBP, P5 .4217) in
patients with more advanced phases of CML, irrespective
of lymphocytosis (Fig. 2e-h). Landmark analyses evaluat-
ing patients with or without lymphocytosis at 3 months
(ie, the median time until the detection of lymphocytosis)
did not demonstrate statistically significant differences in
PFS or OS for patients with or without lymphocytosis,
regardless of disease phase (data not shown).
Side Effects: Pleural Effusion
Pleural effusion is arguably the most unique, common
nonhematologic toxicity after treatment with dasatinib,
and patients have been described with elevated T/NK
lymphocytes in their pleural fluid after such treatment.22
The incidence of pleural effusion was numerically greater
in patients with lymphocytosis in all phases of CML than
in patients without lymphocytosis (Table 4). These differ-
ences were statistically significant in patients with CML-
AP (P5 .0003) and of borderline significance
(P5 .0655) in patients with presumably more advanced
CML-CP who received dasatinib as second-line or third-
line treatment. In an earlier analysis of dasatinib-treated
patients who had lymphocytosis from the DASISION
trial, except for a slight increase in the incidence of rash
(all incidences were grade 1 or 2), there were no differen-
ces in the frequency of other side effects, including diar-
rhea, fatigue, constitutional symptoms, or myalgias.20
TABLE 4. Incidence of Pleural Effusion According to Lymphocytosis
DASISIONa CA180-034b CA180-035b
Variable CML-CP CML-CP CML-AP CML-MBP
Presence of
lymphocytosis
Yes,
n5 90
No,
n5168
Yes,
n5213
No,
n5 449
Yes,
n5 110
No,
n5 206
Yes,
n5 51
No,
n597
Pleural effusion, % 33 26 39 32 53 31 27 27
P .2493 .0655 .0003 1.0000
Abbreviations: CA180-034, 7-year, long-term data from patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP) who were resistant to/intoler-
ant of imatinib in the phase 3 dose-optimization trial; CA180-035, 5-year, long-term data from patients with CML in accelerated phase (CML-AP) or in myeloid-
blast phase (CML-MBP) who were resistant to/intolerant of imatinib in the phase 3 dose-optimization trial for advanced-phase CML; DASISION, Dasatinib Ver-
sus Imatinib Study in Treatment-Naive CML Patients.
a Data shown are for the dasatinib treatment arm only.
b Data include all dasatinib doses.
TABLE 3. Cumulative Incidence of Response According to the Presence or Absence of Lymphocytosis
DASISIONa CA180-034b CA180-035b
Response CML-CP CML-CP CML-AP CML-MBP
Presence of
lymphocytosis
Yes,
n5 90
No,
n5 168 P
Yes,
n5 213
No,
n5 449 P
Yes,
n5 110
No,
n5 206 P
Yes,
n5 51
No,
n597 P
CCyR, % 94 84 .0166 61 47 .0011 45 25 .0004 27 8 .0030
MMR, % 84 73 .0438 52 38 .0010 — — — — — —
MR4.5, % 54 39 .0253 20 12 .0068 — — — — — —
Abbreviations: CA180-034, 7-year, long-term data from patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP) who were resistant to/intoler-
ant of imatinib in the phase 3 dose-optimization trial; CA180-035, 5-year, long-term data from patients with CML in accelerated phase (CML-AP) or in myeloid-
blast phase (CML-MBP) who were resistant to/intolerant of imatinib in the phase 3 dose-optimization trial for advanced-phase CML; CCyR, complete cytoge-
netic response; DASISION, Dasatinib Versus Imatinib Study in Treatment-Naive CML Patients; MMR, major molecular response (breakpoint cluster region/Abel-
son 1 proto-oncogene [BCR-ABL1] transcripts 0.1%); MR4.5, molecular response (BCR-ABL1 transcripts 0.0032%).
a Data shown are for the dasatinib treatment arm only.
b Data include all dasatinib doses.
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DISCUSSION
We demonstrate here for the first time in large studies
that lymphocytosis commonly occurs after treatment
with dasatinib, but not imatinib. Analyses of 3 large
clinical trial populations (n5 1402) in different stages
of CML who received treatment with a variety of dif-
ferent doses of dasatinib and were followed for as long
as 7 years, demonstrate that lymphocytosis develops in
a minimum of 32% of patients and persists for 1
year in at least 50% of such patients. Although immu-
nophenotyping was not done, it is very likely that this
represents expansion of a T/NK-cell population, given
the findings from smaller studies that have character-
ized this proliferation in dasatinib-treated patients.
Lymphocytosis was demonstrated in a similar propor-
tion of patients in all clinical phases and occurred rela-
tively rapidly, with most cases identified within 3 to 5
months after the initiation of dasatinib treatment.
It is also likely that the 32% to 35% incidence of
lymphocytosis represents an underestimate, because 2
consecutive blood samples with an elevated count were
required. The case study in Figure 1 indicates that occa-
sional lymphocyte counts were in the normal range, sug-
gesting that lymphocytosis in some patients may have
been missed because of the use of a somewhat conservative
definition. Some of these fluctuations may be related to
the temporal relation between the ingestion of dasatinib
and the acquisition of the blood sample, as reported in a
recent study demonstrating that increased numbers of
T/NK cells can be detected within 1 to 2 hours after
dasatinib administration, even in normal individuals,
with a correlation between peak blood levels and T/NK
counts.27
It is noteworthy that higher rates of CCyR were
observed in dasatinib-treated patients who had lymphocy-
tosis in all phases of CML, as were the rates of MMR and
deeper MRs (MR4.5) in patients with CML-CP. For the
first time, we demonstrate that PFS and OS are signifi-
cantly longer in patients with imatinib-resistant/intoler-
ant CML-CP who have longer follow-up, which might be
expected if an “immunologic” effect were operative. This
is consistent with other immune-mediated therapies in
which positive effects on longer term outcomes are often
the most prominent findings. Given the substantial
impact of subsequent therapies and the somewhat shorter
follow-up, it is perhaps not unexpected that there was no
significant impact on OS in patients with newly diag-
nosed CML-CP. It is somewhat disappointing that there
was no difference in either PFS or OS in the overall popu-
lation with more advanced stages of CML, given the pre-
vious suggestions regarding unexpectedly long responses
from the many cases and anecdotal observations (Fig. 1).
However, it may be difficult for any putative immunomo-
dulatory effect to overcome the proliferative thrust of
active disease in patients with CML-MBP, although lon-
ger term benefits may occur in patients who can maintain
Figure 1. (a,b) The treatment of a woman who had imatinib-resistant, blast-phase chronic myeloid leukemia with splenomegaly,
fever, and bone pain was complicated by the development of a chronic pleural effusion.
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Figure 2. Progression-free survival (PFS) and overall survival (OS) are illustrated according to the presence of lymphocytosis. (a)
PFS and (b) OS are illustrated in patients who had chronic myeloid leukemia in chronic phase (CML-CP) in the dasatinib treat-
ment arm from the Dasatinib Versus Imatinib Study in Treatment-Naive CML Patients (DASISION) trial (median follow-up, 60.5
months). (c) PFS and (d) OS are illustrated in patients who had previously treated CML-CP from the CA180-034 trial (median
follow-up, 29.8 months). (e) PFS and (f) OS are illustrated in patients who had CML in accelerated phase (CML-AP), and (g) PFS
and (h) OS are illustrated in patients who had CML in myeloid-blast phase (CML-MBP) from the CA180-035 trial (median follow-
up, 6.1 months). †PFS, OS, and lymphocytosis were considered from start of dasatinib treatment.
dasatinib treatment. More detailed studies of the immu-
nologic activity of cells from “exceptional” responders
would be of interest.
Interpretation of these retrospective data may have
been affected by other considerations. For example, the
lymphocyte cutoff we used would not detect lower levels
of T/NK proliferation, which may also influence clinical
outcome. Nonetheless, given the clear correlation between
the occurrence of lymphocytosis and the development of
pleural effusions, the effects on response rate for all stages
of CML, and the significant increase in PFS and OS in
patients with previously treated CML-CP, it appears that
our definition enabled us to capture clinically relevant
associations. Certainly, lymphocytosis after dasatinib
treatment is a consistent and potentially clinically impor-
tant biologic phenomenon, and it is hoped that several of
these questions can be addressed with prospective evalua-
tions of lymphocyte subpopulations in future studies.
The mechanism by which dasatinib induces these
changes is unclear. Lymphocytosis has not been noted af-
ter CML treatment with other TKIs,32-34 and we convinc-
ingly confirm this observation here through analysis of
patients with CML-CP who were treated on a randomized
study of dasatinib versus imatinib. A few trials evaluating
dasatinib in patients with solid tumors have been con-
ducted in which lymphocytosis has not been reported,35
although it could have been missed, because it is not a typ-
ical focus of toxicity assessments. Although primarily tar-
geted against BCR-ABL1 in CML, dasatinib has effects
on multiple kinases and signaling pathways.2,4-6 Indeed,
there had been some initial concern about lymphopenia
and immunosuppression because of the effect of dasatinib
on SRC signaling. Clinical reports have documented
mutations in signal transducer and activator of transcrip-
tion 3 (STAT3) and STAT5B among patients with large
granular lymphocytic leukemia,36,37 a pathway that may
be of interest for patients with CML who have dasatinib-
induced lymphocytosis. Finally, a recent publication eval-
uating dasatinib-treated patients with CML documented
increases in the numbers of functionally active memory
CD4-positive and CD8-positive Th1-type T-helper cells
capable of producing interferon-c, suggesting potential
for an immunomodulatory effect that is undetected in
patients who are taking imatinib or nilotinib.38
In summary, lymphocytosis occurs frequently with
dasatinib treatment, persists for 1 year and is associated
with higher response rates, increased PFS and OS in
patients with CML-CP who are refractory to or intolerant
of imatinib, and the development of pleural effusions.
Prospective studies can better characterize the functional
activity of these lymphocytes and assess whether an immu-
nologic effect against CML cells is detectable, perhaps fo-
cusing on patients with CML-AP or CML in blast crisis
who have unexpectedly long responses to treatment and
those with deep molecular responses who are considering
treatment discontinuation. Given the frequency of the
effect on lymphocytosis in CML, trials using dasatinib to
treat other diseases, possibly in combination with other
immunomodulatory agents, would be of interest. Two tri-
als are currently evaluating dasatinib postautologous and
Figure 2. Continued.
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postallogeneic transplantation, with the aim of augment-
ing the NK proliferation that frequently accompanies
bone marrow reconstitution (NCT01609816 and
NCT01643603).
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